BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34893104)

  • 1. [A Retrospective Analysis of TKI Discontinuation in Patients with CML].
    Zhao XL; Hong M; Qiao C; Sun Q; Zhu H; Wang S; Li JY; Qian SX; Zhu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1746-1751. PubMed ID: 34893104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
    Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
    [No Abstract]   [Full Text] [Related]  

  • 3. [Analysis the influence factors of treatment free remission outcome with chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitors].
    Zhao HF; Zhang Y; Dang LX; Liang JL; Chen SX; Guo Z; Li YL; Zu RR; Gui XD; Wei YP; Song Y
    Zhonghua Yi Xue Za Zhi; 2022 May; 102(20):1523-1529. PubMed ID: 35692068
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
    Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia.
    Shima H; Kada A; Tanizawa A; Sato I; Tono C; Ito M; Yuza Y; Watanabe A; Kamibeppu K; Uryu H; Koh K; Imai C; Yoshida N; Koga Y; Fujita N; Saito AM; Adachi S; Ishii E; Shimada H
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29699. PubMed ID: 35403816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tyrosine kinase inhibitors discontinuation for chronic myeloid leukemia: a multicenter retrospective analysis in China].
    Zhu XJ; You Y; Duan MH; Zhu Y; Liu BC; Chen SN; Du X
    Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):994-997. PubMed ID: 30612400
    [No Abstract]   [Full Text] [Related]  

  • 7. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis on tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia in the real world: experience from single center].
    Yu L; Qin YZ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):754-760. PubMed ID: 29081191
    [No Abstract]   [Full Text] [Related]  

  • 9. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
    Iino M; Yamamoto T; Sakamoto Y
    Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-α may help prevent molecular relapse of chronic myeloid leukemia after the discontinuation of tyrosine kinase inhibitors.
    Jun K; Ya-Zhen Q; Xiao-Su Z; Hong-Xia S; Yue-Yun L; Kai-Yan L; Xiao-Jun H; Hao J
    Ther Adv Hematol; 2021; 12():2040620720986643. PubMed ID: 33613929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
    Dou X; Qin Y; Huang X; Jiang Q
    Oncologist; 2019 Nov; 24(11):e1141-e1147. PubMed ID: 31186377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
    Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
    Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
    Haddad FG; Sasaki K; Issa GC; Garcia-Manero G; Ravandi F; Kadia T; Cortes J; Konopleva M; Pemmaraju N; Alvarado Y; Yilmaz M; Borthakur G; DiNardo C; Jain N; Daver N; Short NJ; Jabbour E; Kantarjian H
    Am J Hematol; 2022 Jul; 97(7):856-864. PubMed ID: 35357036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution.
    Cerveira N; Loureiro B; Bizarro S; Correia C; Torres L; Lisboa S; Vieira J; Santos R; Pereira D; Moreira C; Chacim S; Domingues N; Espírito-Santo A; Oliveira I; Moreira I; Viterbo L; Martins Â; Teixeira MR; Mariz JM
    BMC Cancer; 2018 Dec; 18(1):1245. PubMed ID: 30541488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.
    Hernández-Boluda JC; Pereira A; Pastor-Galán I; Alvarez-Larrán A; Savchuk A; Puerta JM; Sánchez-Pina JM; Collado R; Díaz-González A; Angona A; Sagüés M; García-Gutiérrez V; Boqué C; Osorio S; Vallansot R; Palomera L; Mendizábal A; Casado LF; Pérez-Encinas M; Pérez-López R; Ferrer-Marín F; Sánchez-Guijo F; García C; Heras NL; López-Lorenzo JL; Cervantes F; Steegmann JL;
    Blood Cancer J; 2018 Dec; 8(10):91. PubMed ID: 30504932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.
    Chamoun K; Kantarjian H; Atallah R; Gonzalez GN; Issa GC; Rios MB; Garcia-Manero G; Borthakur G; Ravandi F; Jain N; Daver N; Konopleva M; DiNardo CD; Kadia T; Pemmaraju N; Jabbour E; Cortes J
    J Hematol Oncol; 2019 Jan; 12(1):1. PubMed ID: 30606227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
    Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
    Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.
    Fava C; Rege-Cambrin G; Dogliotti I; Cerrano M; Berchialla P; Dragani M; Rosti G; Castagnetti F; Gugliotta G; Martino B; Gambacorti-Passerini C; Abruzzese E; Elena C; Pregno P; Gozzini A; Capodanno I; Bergamaschi M; Crugnola M; Bocchia M; Galimberti S; Rapezzi D; Iurlo A; Cattaneo D; Latagliata R; Breccia M; Cedrone M; Santoro M; Annunziata M; Levato L; Stagno F; Cavazzini F; Sgherza N; Giai V; Luciano L; Russo S; Musto P; Caocci G; Sorà F; Iuliano F; Lunghi F; Specchia G; Pane F; Ferrero D; Baccarani M; Saglio G
    Haematologica; 2019 Aug; 104(8):1589-1596. PubMed ID: 30819917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania.
    Robin JB; Theron A; Quittet P; Exbrayat C; Gaillard JB; Lavabre-Bertrand T; David S; Saad A; Jourdan E; Cartron G
    Ann Hematol; 2022 May; 101(5):1015-1022. PubMed ID: 35278099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.